Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early...
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
February 22, 2022 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
February 22, 2022 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
December 08, 2021 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals Targeted in Ransomware Incident
November 24, 2021 18:58 ET
|
Supernus Pharmaceuticals, Inc.
The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24,...
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
November 24, 2021 09:12 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
November 23, 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements...
Supernus to Participate in Annual Piper Sandler Healthcare Conference
November 18, 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Upcoming November Investor Conferences
November 10, 2021 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2021 Financial Results
November 03, 2021 16:01 ET
|
Supernus Pharmaceuticals, Inc.
Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020Third quarter 2021 total revenues were $148.5 million, a...